FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease

NCT03562572 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 476

Last updated 2025-08-15

No results posted yet for this study

Summary

To compare FFR guided complete revascularization during the index procedure with usual care in non-STEMI patients with multivessel disease.

Conditions

  • Coronary Artery Disease
  • NSTEMI - Non-ST Segment Elevation MI
  • Fractional Flow Reserve, Myocardial
  • Myocardial Revascularization
  • Percutaneous Coronary Intervention

Interventions

PROCEDURE

Ischemia driven revascularization

In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting during the index intervention

OTHER

Usual care group

In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.

Sponsors & Collaborators

  • Maastricht University Medical Center

    collaborator OTHER
  • Radboud University Medical Center

    collaborator OTHER
  • Jeroen Bosch Ziekenhuis

    collaborator OTHER
  • VieCuri Medical Centre

    collaborator OTHER
  • Gottsegen György Országos Kardiológiai Intézet

    collaborator UNKNOWN
  • Bács-Kiskun County Teaching Hospital

    collaborator OTHER
  • Brno University Hospital

    collaborator OTHER
  • Szeged University

    collaborator OTHER
  • Zuyderland Medisch Centrum

    lead OTHER

Principal Investigators

  • Saman Rasoul, Dr. · Zuyderland MC

  • Arnoud van 't Hof, Prof. Dr. · Zuyderland MC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-07
Primary Completion
2025-07-21
Completion
2027-07-31

Countries

  • Czechia
  • Hungary
  • Netherlands

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03562572 on ClinicalTrials.gov